ID   PIN1_HUMAN              Reviewed;         163 AA.
AC   Q13526; A8K4V9; Q53X75;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1;
DE            EC=5.2.1.8;
DE   AltName: Full=Peptidyl-prolyl cis-trans isomerase Pin1;
DE            Short=PPIase Pin1;
DE   AltName: Full=Rotamase Pin1;
GN   Name=PIN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8606777; DOI=10.1038/380544a0;
RA   Lu K.P., Hanes S.D., Hunter T.;
RT   "A human peptidyl-prolyl isomerase essential for regulation of
RT   mitosis.";
RL   Nature 380:544-547(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH KIF20B, AND MUTAGENESIS OF TYR-23.
RX   PubMed=11470801; DOI=10.1074/jbc.M106207200;
RA   Kamimoto T., Zama T., Aoki R., Muro Y., Hagiwara M.;
RT   "Identification of a novel kinesin-related protein, KRMP1, as a target
RT   for mitotic peptidyl-prolyl isomerase Pin1.";
RL   J. Biol. Chem. 276:37520-37528(2001).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH RAF1.
RX   PubMed=15664191; DOI=10.1016/j.molcel.2004.11.055;
RA   Dougherty M.K., Muller J., Ritt D.A., Zhou M., Zhou X.Z.,
RA   Copeland T.D., Conrads T.P., Veenstra T.D., Lu K.P., Morrison D.K.;
RT   "Regulation of Raf-1 by direct feedback phosphorylation.";
RL   Mol. Cell 17:215-224(2005).
RN   [9]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NEK6.
RX   PubMed=16476580; DOI=10.1016/j.bbrc.2005.12.228;
RA   Chen J., Li L., Zhang Y., Yang H., Wei Y., Zhang L., Liu X., Yu L.;
RT   "Interaction of Pin1 with Nek6 and characterization of their
RT   expression correlation in Chinese hepatocellular carcinoma patients.";
RL   Biochem. Biophys. Res. Commun. 341:1059-1065(2006).
RN   [10]
RP   INTERACTION WITH BTK, AND FUNCTION.
RX   PubMed=16644721; DOI=10.1074/jbc.M603090200;
RA   Yu L., Mohamed A.J., Vargas L., Berglof A., Finn G., Lu K.P.,
RA   Smith C.I.;
RT   "Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase
RT   Pin1.";
RL   J. Biol. Chem. 281:18201-18207(2006).
RN   [11]
RP   FUNCTION IN BCL6 STABILITY REGULATION, INTERACTION WITH BCL6, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=17828269; DOI=10.1038/ni1508;
RA   Phan R.T., Saito M., Kitagawa Y., Means A.R., Dalla-Favera R.;
RT   "Genotoxic stress regulates expression of the proto-oncogene Bcl6 in
RT   germinal center B cells.";
RL   Nat. Immunol. 8:1132-1139(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [13]
RP   INTERACTION WITH ATCAY.
RX   PubMed=18628984; DOI=10.1371/journal.pone.0002686;
RA   Buschdorf J.P., Chew L.L., Soh U.J., Liou Y.C., Low B.C.;
RT   "Nerve growth factor stimulates interaction of Cayman ataxia protein
RT   BNIP-H/Caytaxin with peptidyl-prolyl isomerase Pin1 in differentiating
RT   neurons.";
RL   PLoS ONE 3:E2686-E2686(2008).
RN   [14]
RP   INTERACTION WITH PRKX.
RX   PubMed=19367327; DOI=10.1038/ki.2009.95;
RA   Li X., Hyink D.P., Radbill B., Sudol M., Zhang H., Zheleznova N.N.,
RA   Wilson P.D.;
RT   "Protein kinase-X interacts with Pin-1 and Polycystin-1 during mouse
RT   kidney development.";
RL   Kidney Int. 76:54-62(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-46, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH PML.
RX   PubMed=22033920; DOI=10.1074/jbc.M111.289512;
RA   Lim J.H., Liu Y., Reineke E., Kao H.Y.;
RT   "Mitogen-activated protein kinase extracellular signal-regulated
RT   kinase 2 phosphorylates and promotes Pin1 protein-dependent
RT   promyelocytic leukemia protein turnover.";
RL   J. Biol. Chem. 286:44403-44411(2011).
RN   [18]
RP   FUNCTION, PHOSPHORYLATION AT SER-71, INTERACTION WITH DAPK1,
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF SER-71, AND TISSUE SPECIFICITY.
RX   PubMed=21497122; DOI=10.1016/j.molcel.2011.03.005;
RA   Lee T.H., Chen C.H., Suizu F., Huang P., Schiene-Fischer C., Daum S.,
RA   Zhang Y.J., Goate A., Chen R.H., Zhou X.Z., Lu K.P.;
RT   "Death-associated protein kinase 1 phosphorylates Pin1 and inhibits
RT   its prolyl isomerase activity and cellular function.";
RL   Mol. Cell 42:147-159(2011).
RN   [19]
RP   FUNCTION, INTERACTION WITH FBXW7, AND MUTAGENESIS OF TRP-34 AND
RP   LYS-63.
RX   PubMed=22608923; DOI=10.1016/j.molcel.2012.04.012;
RA   Min S.H., Lau A.W., Lee T.H., Inuzuka H., Wei S., Huang P., Shaik S.,
RA   Lee D.Y., Finn G., Balastik M., Chen C.H., Luo M., Tron A.E.,
RA   Decaprio J.A., Zhou X.Z., Wei W., Lu K.P.;
RT   "Negative regulation of the stability and tumor suppressor function of
RT   Fbw7 by the Pin1 prolyl isomerase.";
RL   Mol. Cell 46:771-783(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   FUNCTION, INTERACTION WITH RBBP8, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF TRP-34 AND CYS-113.
RX   PubMed=23623683; DOI=10.1016/j.molcel.2013.03.023;
RA   Steger M., Murina O., Huehn D., Ferretti L.P., Walser R., Haenggi K.,
RA   Lafranchi L., Neugebauer C., Paliwal S., Janscak P., Gerrits B.,
RA   Del Sal G., Zerbe O., Sartori A.A.;
RT   "Prolyl isomerase PIN1 regulates DNA double-strand break repair by
RT   counteracting DNA end resection.";
RL   Mol. Cell 50:333-343(2013).
RN   [22]
RP   FUNCTION.
RX   PubMed=27561354; DOI=10.1038/ncomms12628;
RA   Ferretti L.P., Himmels S.F., Trenner A., Walker C., von Aesch C.,
RA   Eggenschwiler A., Murina O., Enchev R.I., Peter M., Freire R.,
RA   Porro A., Sartori A.A.;
RT   "Cullin3-KLHL15 ubiquitin ligase mediates CtIP protein turnover to
RT   fine-tune DNA-end resection.";
RL   Nat. Commun. 7:12628-12628(2016).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS).
RX   PubMed=9200606; DOI=10.1016/S0092-8674(00)80273-1;
RA   Ranganathan R., Lu K.P., Hunter T., Noel J.P.;
RT   "Structural and functional analysis of the mitotic rotamase Pin1
RT   suggests substrate recognition is phosphorylation dependent.";
RL   Cell 89:875-886(1997).
CC   -!- FUNCTION: Peptidyl-prolyl cis/trans isomerase (PPIase) that binds
CC       to and isomerizes specific phosphorylated Ser/Thr-Pro (pSer/Thr-
CC       Pro) motifs. By inducing conformational changes in a subset of
CC       phosphorylated proteins, acts as a molecular switch in multiple
CC       cellular processes (PubMed:21497122, PubMed:22033920, Ref. 21).
CC       Displays a preference for acidic residues located N-terminally to
CC       the proline bond to be isomerized. Regulates mitosis presumably by
CC       interacting with NIMA and attenuating its mitosis-promoting
CC       activity. Down-regulates kinase activity of BTK (PubMed:16644721).
CC       Can transactivate multiple oncogenes and induce centrosome
CC       amplification, chromosome instability and cell transformation.
CC       Required for the efficient dephosphorylation and recycling of RAF1
CC       after mitogen activation (PubMed:15664191). Binds and targets PML
CC       and BCL6 for degradation in a phosphorylation-dependent manner
CC       (PubMed:17828269). Acts as a regulator of JNK cascade by binding
CC       to phosphorylated FBXW7, disrupting FBXW7 dimerization and
CC       promoting FBXW7 autoubiquitination and degradation: degradation of
CC       FBXW7 leads to subsequent stabilization of JUN (PubMed:22608923).
CC       May facilitate the ubiquitination and proteasomal degradation of
CC       RBBP8/CtIP through CUL3/KLHL15 E3 ubiquitin-protein ligase
CC       complex, hence favors DNA double-strand repair through error-prone
CC       non-homologous end joining (NHEJ) over error-free, RBBP8-mediated
CC       homologous recombination (HR) (PubMed:23623683, PubMed:27561354).
CC       {ECO:0000269|PubMed:15664191, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:21497122,
CC       ECO:0000269|PubMed:22033920, ECO:0000269|PubMed:22608923,
CC       ECO:0000269|PubMed:23623683, ECO:0000269|PubMed:27561354}.
CC   -!- CATALYTIC ACTIVITY: Peptidylproline (omega=180) = peptidylproline
CC       (omega=0).
CC   -!- SUBUNIT: Interacts with STIL. Interacts with KIF20B. Interacts
CC       with NEK6. Interacts (via WW domain) with PRKX. Interacts with
CC       BTK. Interacts (via PpiC domain) with DAPK1. Interacts with the
CC       phosphorylated form of RAF1. Interacts (via WW domain) with ATCAY;
CC       upon NGF stimulation. Interacts with PML (isoform PML-4) and BCL-
CC       6. Interacts with FBXW7, disrupting FBXW7 dimerization and
CC       promoting FBXW7 autoubiquitination and degradation
CC       (PubMed:22608923). Directly interacts with RBBP8/CtIP; this
CC       interaction depends upon RBBP8 phosphorylation (PubMed:23623683).
CC       {ECO:0000269|PubMed:11470801, ECO:0000269|PubMed:15664191,
CC       ECO:0000269|PubMed:16476580, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:18628984,
CC       ECO:0000269|PubMed:19367327, ECO:0000269|PubMed:21497122,
CC       ECO:0000269|PubMed:22033920, ECO:0000269|PubMed:22608923,
CC       ECO:0000269|PubMed:23623683}.
CC   -!- INTERACTION:
CC       Q9NYB9:ABI2; NbExp=3; IntAct=EBI-714158, EBI-743598;
CC       Q6UY14-3:ADAMTSL4; NbExp=3; IntAct=EBI-714158, EBI-10173507;
CC       P78563:ADARB1; NbExp=12; IntAct=EBI-714158, EBI-2967304;
CC       Q4VCS5-2:AMOT; NbExp=3; IntAct=EBI-714158, EBI-3891843;
CC       Q6AI12:ANKRD40; NbExp=5; IntAct=EBI-714158, EBI-2838246;
CC       P05067-4:APP; NbExp=2; IntAct=EBI-714158, EBI-302641;
CC       P85298-4:ARHGAP8; NbExp=25; IntAct=EBI-714158, EBI-9523517;
CC       D3DTR7:ARHGEF15; NbExp=3; IntAct=EBI-714158, EBI-10176602;
CC       P35520:CBS; NbExp=3; IntAct=EBI-714158, EBI-740135;
CC       Q52MB2:CCDC184; NbExp=5; IntAct=EBI-714158, EBI-10179526;
CC       Q15131:CDK10; NbExp=5; IntAct=EBI-714158, EBI-1646959;
CC       D3DR37:CEP55; NbExp=3; IntAct=EBI-714158, EBI-10173536;
CC       Q8TAP6:CEP76; NbExp=5; IntAct=EBI-714158, EBI-742887;
CC       Q969H4:CNKSR1; NbExp=5; IntAct=EBI-714158, EBI-741671;
CC       O75553:DAB1; NbExp=3; IntAct=EBI-714158, EBI-7875264;
CC       O15409:FOXP2; NbExp=5; IntAct=EBI-714158, EBI-983612;
CC       Q08379:GOLGA2; NbExp=3; IntAct=EBI-714158, EBI-618309;
CC       P31424-2:Grm5 (xeno); NbExp=3; IntAct=EBI-714158, EBI-8830305;
CC       Q3UVX5:Grm5 (xeno); NbExp=2; IntAct=EBI-714158, EBI-8795045;
CC       Q96MH2:HEXIM2; NbExp=7; IntAct=EBI-714158, EBI-5460660;
CC       Q8IX15-3:HOMEZ; NbExp=3; IntAct=EBI-714158, EBI-10172004;
CC       Q13422:IKZF1; NbExp=3; IntAct=EBI-714158, EBI-745305;
CC       Q9UKT9:IKZF3; NbExp=5; IntAct=EBI-714158, EBI-747204;
CC       P51617:IRAK1; NbExp=10; IntAct=EBI-714158, EBI-358664;
CC       Q96AA8:JAKMIP2; NbExp=3; IntAct=EBI-714158, EBI-752007;
CC       Q15323:KRT31; NbExp=5; IntAct=EBI-714158, EBI-948001;
CC       O76015:KRT38; NbExp=5; IntAct=EBI-714158, EBI-1047263;
CC       Q6A162:KRT40; NbExp=3; IntAct=EBI-714158, EBI-10171697;
CC       P60409:KRTAP10-7; NbExp=3; IntAct=EBI-714158, EBI-10172290;
CC       P60411:KRTAP10-9; NbExp=3; IntAct=EBI-714158, EBI-10172052;
CC       Q9BYR5:KRTAP4-2; NbExp=3; IntAct=EBI-714158, EBI-10172511;
CC       P31938:Map2k1 (xeno); NbExp=4; IntAct=EBI-714158, EBI-298860;
CC       Q63932:Map2k2 (xeno); NbExp=12; IntAct=EBI-714158, EBI-397724;
CC       P41279:MAP3K8; NbExp=8; IntAct=EBI-714158, EBI-354900;
CC       Q99750:MDFI; NbExp=6; IntAct=EBI-714158, EBI-724076;
CC       A4D127:MEOX2; NbExp=5; IntAct=EBI-714158, EBI-10172134;
CC       Q5JR59:MTUS2; NbExp=3; IntAct=EBI-714158, EBI-742948;
CC       Q15742:NAB2; NbExp=5; IntAct=EBI-714158, EBI-8641936;
CC       Q9HC98:NEK6; NbExp=3; IntAct=EBI-714158, EBI-740364;
CC       Q15233:NONO; NbExp=4; IntAct=EBI-714158, EBI-350527;
CC       Q15233-2:NONO; NbExp=3; IntAct=EBI-714158, EBI-10203843;
CC       P46531:NOTCH1; NbExp=9; IntAct=EBI-714158, EBI-636374;
CC       P37198:NUP62; NbExp=5; IntAct=EBI-714158, EBI-347978;
CC       Q8ND90:PNMA1; NbExp=3; IntAct=EBI-714158, EBI-302345;
CC       Q96M27:PRRC1; NbExp=3; IntAct=EBI-714158, EBI-2560879;
CC       Q7Z5J4:RAI1; NbExp=4; IntAct=EBI-714158, EBI-743815;
CC       Q99708-2:RBBP8; NbExp=3; IntAct=EBI-714158, EBI-10203615;
CC       Q93062:RBPMS; NbExp=4; IntAct=EBI-714158, EBI-740322;
CC       Q13950:RUNX2; NbExp=7; IntAct=EBI-714158, EBI-976402;
CC       Q13342:SP140; NbExp=4; IntAct=EBI-714158, EBI-2865100;
CC       Q8NA61:SPERT; NbExp=3; IntAct=EBI-714158, EBI-741724;
CC       Q9BWW4:SSBP3; NbExp=5; IntAct=EBI-714158, EBI-2902395;
CC       Q9BWG4:SSBP4; NbExp=3; IntAct=EBI-714158, EBI-744719;
CC       Q9BR01:SULT4A1; NbExp=4; IntAct=EBI-714158, EBI-6690555;
CC       O00267:SUPT5H; NbExp=3; IntAct=EBI-714158, EBI-710464;
CC       Q8N5C8:TAB3; NbExp=3; IntAct=EBI-714158, EBI-359964;
CC       P15884:TCF4; NbExp=3; IntAct=EBI-714158, EBI-533224;
CC       Q9BT49:THAP7; NbExp=3; IntAct=EBI-714158, EBI-741350;
CC       Q15025:TNIP1; NbExp=6; IntAct=EBI-714158, EBI-357849;
CC       P04637:TP53; NbExp=12; IntAct=EBI-714158, EBI-366083;
CC       Q13077:TRAF1; NbExp=3; IntAct=EBI-714158, EBI-359224;
CC       Q12933:TRAF2; NbExp=6; IntAct=EBI-714158, EBI-355744;
CC       Q15654:TRIP6; NbExp=3; IntAct=EBI-714158, EBI-742327;
CC       Q9Y3Q8:TSC22D4; NbExp=6; IntAct=EBI-714158, EBI-739485;
CC       O43829:ZBTB14; NbExp=3; IntAct=EBI-714158, EBI-10176632;
CC       O15209:ZBTB22; NbExp=3; IntAct=EBI-714158, EBI-723574;
CC       O15156:ZBTB7B; NbExp=3; IntAct=EBI-714158, EBI-740434;
CC       Q96C00:ZBTB9; NbExp=5; IntAct=EBI-714158, EBI-395708;
CC       Q8NF64:ZMIZ2; NbExp=4; IntAct=EBI-714158, EBI-745786;
CC       Q8NF64-2:ZMIZ2; NbExp=3; IntAct=EBI-714158, EBI-10182121;
CC       Q96AF5:ZNF446; NbExp=3; IntAct=EBI-714158, EBI-740232;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16476580,
CC       ECO:0000269|PubMed:23623683}. Nucleus speckle
CC       {ECO:0000269|PubMed:21497122}. Cytoplasm
CC       {ECO:0000269|PubMed:21497122}. Note=Colocalizes with NEK6 in the
CC       nucleus (PubMed:16476580). Mainly localized in the nucleus but
CC       phosphorylation at Ser-71 by DAPK1 results in inhibition of its
CC       nuclear localization (PubMed:21497122).
CC       {ECO:0000269|PubMed:16476580}.
CC   -!- TISSUE SPECIFICITY: The phosphorylated form at Ser-71 is expressed
CC       in normal breast tissue cells but not in breast cancer cells.
CC       {ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:21497122}.
CC   -!- DOMAIN: The WW domain is required for the interaction with STIL
CC       and KIF20B.
CC   -!- PTM: Phosphorylation at Ser-71 by DAPK1 results in inhibition of
CC       its catalytic activity, nuclear localization, and its ability to
CC       induce centrosome amplification, chromosome instability and cell
CC       transformation. {ECO:0000269|PubMed:21497122}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U49070; AAC50492.1; -; mRNA.
DR   EMBL; CR407654; CAG28582.1; -; mRNA.
DR   EMBL; BT019331; AAV38138.1; -; mRNA.
DR   EMBL; AK291074; BAF83763.1; -; mRNA.
DR   EMBL; CH471106; EAW84057.1; -; Genomic_DNA.
DR   EMBL; BC002899; AAH02899.1; -; mRNA.
DR   CCDS; CCDS12220.1; -.
DR   PIR; S68520; S68520.
DR   RefSeq; NP_006212.1; NM_006221.3.
DR   UniGene; Hs.465849; -.
DR   PDB; 1F8A; X-ray; 1.84 A; B=1-163.
DR   PDB; 1I6C; NMR; -; A=6-44.
DR   PDB; 1I8G; NMR; -; B=6-44.
DR   PDB; 1I8H; NMR; -; B=6-44.
DR   PDB; 1NMV; NMR; -; A=1-163.
DR   PDB; 1NMW; NMR; -; A=50-163.
DR   PDB; 1PIN; X-ray; 1.35 A; A=1-163.
DR   PDB; 1ZCN; X-ray; 1.90 A; A=1-161.
DR   PDB; 2F21; X-ray; 1.50 A; A=1-162.
DR   PDB; 2ITK; X-ray; 1.45 A; A=1-163.
DR   PDB; 2KBU; NMR; -; A=6-39.
DR   PDB; 2KCF; NMR; -; A=6-39.
DR   PDB; 2LB3; NMR; -; A=6-41.
DR   PDB; 2M8I; NMR; -; A=1-39.
DR   PDB; 2M8J; NMR; -; A=1-39.
DR   PDB; 2M9E; NMR; -; A=6-15, A=22-39.
DR   PDB; 2M9F; NMR; -; A=6-15, A=22-39.
DR   PDB; 2M9I; NMR; -; A=6-39.
DR   PDB; 2M9J; NMR; -; A=6-39.
DR   PDB; 2N1O; NMR; -; A=7-39.
DR   PDB; 2Q5A; X-ray; 1.50 A; A=1-163.
DR   PDB; 2RUC; NMR; -; A=51-163.
DR   PDB; 2RUD; NMR; -; A=51-163.
DR   PDB; 2RUQ; NMR; -; A=51-163.
DR   PDB; 2RUR; NMR; -; A=51-163.
DR   PDB; 2XP3; X-ray; 2.00 A; A=1-163.
DR   PDB; 2XP4; X-ray; 1.80 A; A=1-163.
DR   PDB; 2XP5; X-ray; 1.90 A; A=1-163.
DR   PDB; 2XP6; X-ray; 1.90 A; A=1-163.
DR   PDB; 2XP7; X-ray; 2.00 A; A=1-163.
DR   PDB; 2XP8; X-ray; 2.10 A; A=1-163.
DR   PDB; 2XP9; X-ray; 1.90 A; A=1-163.
DR   PDB; 2XPA; X-ray; 1.90 A; A=1-163.
DR   PDB; 2XPB; X-ray; 2.00 A; A=1-163.
DR   PDB; 2ZQS; X-ray; 1.90 A; A=1-163.
DR   PDB; 2ZQT; X-ray; 1.46 A; A=1-163.
DR   PDB; 2ZQU; X-ray; 2.50 A; A=1-163.
DR   PDB; 2ZQV; X-ray; 2.50 A; A=1-163.
DR   PDB; 2ZR4; X-ray; 2.00 A; A=1-163.
DR   PDB; 2ZR5; X-ray; 2.60 A; A=1-163.
DR   PDB; 2ZR6; X-ray; 3.20 A; A=1-163.
DR   PDB; 3I6C; X-ray; 1.30 A; A/B=45-163.
DR   PDB; 3IK8; X-ray; 1.85 A; A/B=45-163.
DR   PDB; 3IKD; X-ray; 2.00 A; A/B=45-163.
DR   PDB; 3IKG; X-ray; 1.86 A; A/B=45-163.
DR   PDB; 3JYJ; X-ray; 1.87 A; A/B=45-163.
DR   PDB; 3KAB; X-ray; 2.19 A; A=1-163.
DR   PDB; 3KAC; X-ray; 2.00 A; A/B=45-163.
DR   PDB; 3KAD; X-ray; 1.95 A; A=1-163.
DR   PDB; 3KAF; X-ray; 2.30 A; A=1-163.
DR   PDB; 3KAG; X-ray; 1.90 A; A=1-163.
DR   PDB; 3KAH; X-ray; 2.30 A; A=1-163.
DR   PDB; 3KAI; X-ray; 1.90 A; A=1-163.
DR   PDB; 3KCE; X-ray; 1.90 A; A=1-163.
DR   PDB; 3NTP; X-ray; 1.76 A; A=1-163.
DR   PDB; 3ODK; X-ray; 2.30 A; A=1-163.
DR   PDB; 3OOB; X-ray; 1.89 A; A=1-163.
DR   PDB; 3TC5; X-ray; 1.40 A; A=1-163.
DR   PDB; 3TCZ; X-ray; 2.10 A; A=6-163.
DR   PDB; 3TDB; X-ray; 2.27 A; A=6-163.
DR   PDB; 3WH0; X-ray; 1.60 A; A=1-163.
DR   PDB; 4GWT; X-ray; 2.25 A; A=6-39.
DR   PDB; 4GWV; X-ray; 3.05 A; A=6-39.
DR   PDB; 4QIB; X-ray; 1.86 A; A=7-163.
DR   PDB; 4TNS; X-ray; 1.33 A; A/B=43-163.
DR   PDB; 4TYO; X-ray; 1.75 A; A/B=45-163.
DR   PDB; 4U84; X-ray; 1.78 A; A=1-163.
DR   PDB; 4U85; X-ray; 1.70 A; A=1-163.
DR   PDB; 4U86; X-ray; 1.60 A; A=1-163.
DR   PDB; 5B3W; X-ray; 2.40 A; A/B=5-15.
DR   PDB; 5B3X; X-ray; 2.40 A; A=5-15.
DR   PDB; 5B3Y; X-ray; 1.90 A; A=5-23.
DR   PDB; 5B3Z; X-ray; 2.30 A; A/B/C/D=5-39.
DR   PDB; 5BMY; X-ray; 2.00 A; A=5-29.
DR   PDBsum; 1F8A; -.
DR   PDBsum; 1I6C; -.
DR   PDBsum; 1I8G; -.
DR   PDBsum; 1I8H; -.
DR   PDBsum; 1NMV; -.
DR   PDBsum; 1NMW; -.
DR   PDBsum; 1PIN; -.
DR   PDBsum; 1ZCN; -.
DR   PDBsum; 2F21; -.
DR   PDBsum; 2ITK; -.
DR   PDBsum; 2KBU; -.
DR   PDBsum; 2KCF; -.
DR   PDBsum; 2LB3; -.
DR   PDBsum; 2M8I; -.
DR   PDBsum; 2M8J; -.
DR   PDBsum; 2M9E; -.
DR   PDBsum; 2M9F; -.
DR   PDBsum; 2M9I; -.
DR   PDBsum; 2M9J; -.
DR   PDBsum; 2N1O; -.
DR   PDBsum; 2Q5A; -.
DR   PDBsum; 2RUC; -.
DR   PDBsum; 2RUD; -.
DR   PDBsum; 2RUQ; -.
DR   PDBsum; 2RUR; -.
DR   PDBsum; 2XP3; -.
DR   PDBsum; 2XP4; -.
DR   PDBsum; 2XP5; -.
DR   PDBsum; 2XP6; -.
DR   PDBsum; 2XP7; -.
DR   PDBsum; 2XP8; -.
DR   PDBsum; 2XP9; -.
DR   PDBsum; 2XPA; -.
DR   PDBsum; 2XPB; -.
DR   PDBsum; 2ZQS; -.
DR   PDBsum; 2ZQT; -.
DR   PDBsum; 2ZQU; -.
DR   PDBsum; 2ZQV; -.
DR   PDBsum; 2ZR4; -.
DR   PDBsum; 2ZR5; -.
DR   PDBsum; 2ZR6; -.
DR   PDBsum; 3I6C; -.
DR   PDBsum; 3IK8; -.
DR   PDBsum; 3IKD; -.
DR   PDBsum; 3IKG; -.
DR   PDBsum; 3JYJ; -.
DR   PDBsum; 3KAB; -.
DR   PDBsum; 3KAC; -.
DR   PDBsum; 3KAD; -.
DR   PDBsum; 3KAF; -.
DR   PDBsum; 3KAG; -.
DR   PDBsum; 3KAH; -.
DR   PDBsum; 3KAI; -.
DR   PDBsum; 3KCE; -.
DR   PDBsum; 3NTP; -.
DR   PDBsum; 3ODK; -.
DR   PDBsum; 3OOB; -.
DR   PDBsum; 3TC5; -.
DR   PDBsum; 3TCZ; -.
DR   PDBsum; 3TDB; -.
DR   PDBsum; 3WH0; -.
DR   PDBsum; 4GWT; -.
DR   PDBsum; 4GWV; -.
DR   PDBsum; 4QIB; -.
DR   PDBsum; 4TNS; -.
DR   PDBsum; 4TYO; -.
DR   PDBsum; 4U84; -.
DR   PDBsum; 4U85; -.
DR   PDBsum; 4U86; -.
DR   PDBsum; 5B3W; -.
DR   PDBsum; 5B3X; -.
DR   PDBsum; 5B3Y; -.
DR   PDBsum; 5B3Z; -.
DR   PDBsum; 5BMY; -.
DR   ProteinModelPortal; Q13526; -.
DR   SMR; Q13526; -.
DR   BioGrid; 111317; 233.
DR   DIP; DIP-29306N; -.
DR   IntAct; Q13526; 190.
DR   MINT; MINT-86298; -.
DR   STRING; 9606.ENSP00000247970; -.
DR   BindingDB; Q13526; -.
DR   ChEMBL; CHEMBL2288; -.
DR   DrugBank; DB01766; Beta-(2-Naphthyl)-Alanine.
DR   iPTMnet; Q13526; -.
DR   PhosphoSitePlus; Q13526; -.
DR   BioMuta; PIN1; -.
DR   DMDM; 3024406; -.
DR   EPD; Q13526; -.
DR   MaxQB; Q13526; -.
DR   PaxDb; Q13526; -.
DR   PeptideAtlas; Q13526; -.
DR   PRIDE; Q13526; -.
DR   DNASU; 5300; -.
DR   Ensembl; ENST00000247970; ENSP00000247970; ENSG00000127445.
DR   Ensembl; ENST00000588695; ENSP00000466962; ENSG00000127445.
DR   GeneID; 5300; -.
DR   KEGG; hsa:5300; -.
DR   UCSC; uc002mml.3; human.
DR   CTD; 5300; -.
DR   DisGeNET; 5300; -.
DR   GeneCards; PIN1; -.
DR   HGNC; HGNC:8988; PIN1.
DR   HPA; CAB004528; -.
DR   HPA; CAB009326; -.
DR   HPA; HPA068650; -.
DR   MIM; 601052; gene.
DR   neXtProt; NX_Q13526; -.
DR   OpenTargets; ENSG00000127445; -.
DR   PharmGKB; PA33320; -.
DR   eggNOG; KOG3259; Eukaryota.
DR   eggNOG; COG0760; LUCA.
DR   GeneTree; ENSGT00640000091578; -.
DR   HOGENOM; HOG000275331; -.
DR   HOVERGEN; HBG002101; -.
DR   InParanoid; Q13526; -.
DR   KO; K09578; -.
DR   OMA; DEVQCLH; -.
DR   OrthoDB; EOG091G0RO7; -.
DR   PhylomeDB; Q13526; -.
DR   TreeFam; TF101101; -.
DR   BRENDA; 5.2.1.8; 2681.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-HSA-936440; Negative regulators of RIG-I/MDA5 signaling.
DR   SignaLink; Q13526; -.
DR   SIGNOR; Q13526; -.
DR   ChiTaRS; PIN1; human.
DR   EvolutionaryTrace; Q13526; -.
DR   GeneWiki; PIN1; -.
DR   GenomeRNAi; 5300; -.
DR   PRO; PR:Q13526; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000127445; -.
DR   CleanEx; HS_PIN1; -.
DR   ExpressionAtlas; Q13526; baseline and differential.
DR   Genevisible; Q13526; HS.
DR   GO; GO:0005829; C:cytosol; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030496; C:midbody; IDA:MGI.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0032794; F:GTPase activating protein binding; IPI:BHF-UCL.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IPI:BHF-UCL.
DR   GO; GO:0003774; F:motor activity; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0003755; F:peptidyl-prolyl cis-trans isomerase activity; IDA:BHF-UCL.
DR   GO; GO:0050815; F:phosphoserine binding; IDA:BHF-UCL.
DR   GO; GO:0050816; F:phosphothreonine binding; IDA:BHF-UCL.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:2000146; P:negative regulation of cell motility; IDA:BHF-UCL.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0030182; P:neuron differentiation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0061051; P:positive regulation of cell growth involved in cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IMP:BHF-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IGI:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein transferase activity; IDA:BHF-UCL.
DR   GO; GO:0000413; P:protein peptidyl-prolyl isomerization; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0050821; P:protein stabilization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032465; P:regulation of cytokinesis; IMP:MGI.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:ProtInc.
DR   GO; GO:0060393; P:regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:1900180; P:regulation of protein localization to nucleus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0050808; P:synapse organization; ISS:ParkinsonsUK-UCL.
DR   InterPro; IPR000297; PPIase_PpiC.
DR   InterPro; IPR023058; PPIase_PpiC_CS.
DR   InterPro; IPR001202; WW_dom.
DR   Pfam; PF00639; Rotamase; 1.
DR   Pfam; PF00397; WW; 1.
DR   SMART; SM00456; WW; 1.
DR   SUPFAM; SSF51045; SSF51045; 1.
DR   PROSITE; PS01096; PPIC_PPIASE_1; 1.
DR   PROSITE; PS50198; PPIC_PPIASE_2; 1.
DR   PROSITE; PS01159; WW_DOMAIN_1; 1.
DR   PROSITE; PS50020; WW_DOMAIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell cycle; Complete proteome; Cytoplasm;
KW   Isomerase; Nucleus; Phosphoprotein; Reference proteome; Rotamase.
FT   CHAIN         1    163       Peptidyl-prolyl cis-trans isomerase NIMA-
FT                                interacting 1.
FT                                /FTId=PRO_0000193435.
FT   DOMAIN        5     39       WW. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN       52    163       PpiC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00278}.
FT   MOD_RES      43     43       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      46     46       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      71     71       Phosphoserine; by DAPK1.
FT                                {ECO:0000269|PubMed:21497122}.
FT   MOD_RES     108    108       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332}.
FT   MUTAGEN      23     23       Y->A: Reduced affinity for KIF20B.
FT                                {ECO:0000269|PubMed:11470801}.
FT   MUTAGEN      34     34       W->A: Loss of binding to phosphorylated
FT                                target proteins, including to
FT                                phosphorylated RBBP8/CtIP; decrease in
FT                                DNA repair of double-strand breaks by
FT                                homologous recombination less efficient
FT                                than that observed with wild-type
FT                                protein. {ECO:0000269|PubMed:22608923,
FT                                ECO:0000269|PubMed:23623683}.
FT   MUTAGEN      63     63       K->A: Loss of peptidyl-prolyl cis/trans
FT                                isomerase activity.
FT                                {ECO:0000269|PubMed:22608923}.
FT   MUTAGEN      71     71       S->D,E: Loss of peptidyl-prolyl cis/trans
FT                                isomerase activity, nuclear localization
FT                                and cellular function.
FT                                {ECO:0000269|PubMed:21497122}.
FT   MUTAGEN     113    113       C->A: Loss of peptidyl-prolyl cis/trans
FT                                isomerase activity; decrease in DNA
FT                                repair of double-strand breaks by
FT                                homologous recombination slightly less
FT                                efficient than that observed with wild-
FT                                type protein. No effect on RBBP8/CtIP.
FT                                {ECO:0000269|PubMed:23623683}.
FT   STRAND       11     15       {ECO:0000244|PDB:1PIN}.
FT   TURN         17     19       {ECO:0000244|PDB:3TC5}.
FT   STRAND       22     26       {ECO:0000244|PDB:1PIN}.
FT   TURN         27     29       {ECO:0000244|PDB:1PIN}.
FT   STRAND       32     35       {ECO:0000244|PDB:1PIN}.
FT   STRAND       39     41       {ECO:0000244|PDB:1I6C}.
FT   STRAND       53     62       {ECO:0000244|PDB:3I6C}.
FT   STRAND       67     69       {ECO:0000244|PDB:3I6C}.
FT   STRAND       75     77       {ECO:0000244|PDB:3I6C}.
FT   HELIX        82     98       {ECO:0000244|PDB:3I6C}.
FT   STRAND       99    101       {ECO:0000244|PDB:3I6C}.
FT   HELIX       103    110       {ECO:0000244|PDB:3I6C}.
FT   HELIX       114    118       {ECO:0000244|PDB:3I6C}.
FT   STRAND      121    126       {ECO:0000244|PDB:3I6C}.
FT   HELIX       127    129       {ECO:0000244|PDB:2RUD}.
FT   HELIX       132    140       {ECO:0000244|PDB:3I6C}.
FT   HELIX       144    146       {ECO:0000244|PDB:5B3Y}.
FT   STRAND      150    152       {ECO:0000244|PDB:3I6C}.
FT   STRAND      155    163       {ECO:0000244|PDB:3I6C}.
SQ   SEQUENCE   163 AA;  18243 MW;  35391AF40B7D1E13 CRC64;
     MADEEKLPPG WEKRMSRSSG RVYYFNHITN ASQWERPSGN SSSGGKNGQG EPARVRCSHL
     LVKHSQSRRP SSWRQEKITR TKEEALELIN GYIQKIKSGE EDFESLASQF SDCSSAKARG
     DLGAFSRGQM QKPFEDASFA LRTGEMSGPV FTDSGIHIIL RTE
//
